Overview

Stress Experience Following Psilocybin

Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the importance in the acute stress response induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with a placebo or metyrapone, a cortisol synthesis inhibitor medication, on four different occasions.
Phase:
PHASE2
Details
Lead Sponsor:
University of Calgary
Treatments:
Metyrapone
Psilocybin